Navigation

Claforan

Claforan (Cefotaxime) side effects drug center

  • Related Drugs
  • Claforan Side Effects Center

    What Is Claforan?

    Claforan (cefotaxime sodium) injection is a cephalosporin antibiotic used to treat many kinds of bacterial infections, including severe or life-threatening forms. Claforan is also used to prevent infections in people having surgery. Claforan is available in generic form.

    What Are Side Effects of Claforan?

    Common side effects of Claforan include:

    Tell your doctor if you have serious side effects of Claforan including:

    • dark urine,
    • easy bruising or bleeding,
    • fast/pounding/irregular heartbeat,
    • seizures,
    • unusual weakness,
    • yellowing eyes or skin, or
    • mental/mood changes (such as confusion).

    Dosage for Claforan

    Dose of Claforan is dependent upon the condition being treated, and its severity. Pediatric dose is determined by the child's weight and condition being treated.

    What Drugs, Substances, or Supplements Interact with Claforan?

    Claforan may interact with other antibiotics. Other drugs may also interact with Claforan. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

    Claforan During Pregnancy and Breastfeeding

    This medication is not expected to be harmful to a fetus. Tell your doctor if you are pregnant before using Claforan. This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breastfeeding.

    Additional Information

    Our Claforan (cefotaxime sodium) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

    Claforan Consumer Information

    Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).

    Call your doctor at once if you have:

    • severe stomach pain, diarrhea that is watery or bloody (even if it occurs months after your last dose);
    • burning, irritation, or skin changes where the injection was given;
    • dark urine, jaundice (yellowing of the skin or eyes);
    • a seizure;
    • fever, chills, tiredness; or
    • easy bruising, unusual bleeding, pale skin, cold hands and feet.

    Common side effects may include:

    • pain, bruising, swelling, or other irritation where the injection was given;
    • diarrhea;
    • fever; or
    • rash, itching.

    This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Read the entire detailed patient monograph for Claforan (Cefotaxime)

    Claforan Professional Information

    SIDE EFFECTS

    Clinical Trials Experience

    CLAFORAN is generally well tolerated. The most common adverse reactions have been local reactions following IM or IV injection. Other adverse reactions have been encountered infrequently.

    The most frequent adverse reactions (greater than 1%) are:

    Local (4.3%) -Injection site inflammation with IV administration. Pain, induration, and tenderness after IM injection.

    Hypersensitivity (2.4%) -Rash, pruritus, fever, eosinophilia.

    Gastrointestinal (1.4%) -Colitis, diarrhea, nausea, and vomiting.

    Symptoms of pseudomembranous colitis can appear during or after antibiotic treatment.

    Nausea and vomiting have been reported rarely.

    Less frequent adverse reactions (less than 1%) are:

    Hematologic System -Neutropenia, transient leukopenia, have been reported. Some individuals have developed positive direct Coombs Tests during treatment with CLAFORAN and other cephalosporin antibiotics.

    Genitourinary System -Moniliasis, vaginitis.

    Central Nervous System -Headache.

    Liver -Transient elevations in AST, ALT, serum LDH, and serum alkaline phosphatase levels have been reported.

    Kidney -As with some other cephalosporins, transient elevations of BUN have been occasionally observed with CLAFORAN.

    Post-Marketing Experience

    The following adverse reactions have been identified during post-approval use of CLAFORAN. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Cardiovascular System -Potentially life-threatening arrhythmias following rapid (less than 60 seconds) bolus administration via central venous catheter have been observed.

    Central Nervous System -Administration of high doses of beta-lactam antibiotics, including cefotaxime, particularly in patients with renal insufficiency may result in encephalopathy (e.g. impairment of consciousness, abnormal movements and convulsions).

    Cutaneous -As with other cephalosporins, isolated cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have been reported.

    Hematologic System -Hemolytic anemia, agranulocytosis, thrombocytopenia.

    Hypersensitivity -Anaphylaxis (e.g., angioedema, bronchospasm, malaise possibly culminating in shock), urticaria.

    Kidney -Interstitial nephritis, transient elevations of creatinine.

    Liver -Hepatitis, jaundice, cholestasis, elevations of gamma GT and bilirubin.

    Cephalosporin Class Labeling

    In addition to the adverse reactions listed above which have been observed in patients treated with cefotaxime sodium, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: allergic reactions, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, and false-positive test for urinary glucose.

    Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. See DOSAGE AND ADMINISTRATION and OVERDOSAGE. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

    Read the entire FDA prescribing information for Claforan (Cefotaxime)

    © Claforan Patient Information is supplied by Cerner Multum, Inc. and Claforan Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.